Evidence map›Paper›PMID 32946534›Full record

ArticlePloS one2020

Binding of omeprazole to protein targets identified by monoclonal antibodies.

Naw May Pearl Cartee, Michael M Wang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Omeprazole activation of CD4+ and CD8+ T-cells through off-target covalent modification of cellular proteins.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Structural Relationships to Efficacy for Prazole-Derived Antivirals.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  8. Review
  9. Microorganisms · 2024
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Naw May Pearl CarteeDepartment of Neurology, University of Michigan, Ann Arbor, MI, United States of America.
Michael M WangDepartment of Neurology, University of Michigan, Ann Arbor, MI, United States of America.ORCID 0000-0002-5670-2496
University of Michigan · US

Funding

NOTCH3 N-terminal fragmentation in cerebral small vessel diseaseR01NS099160 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, MICHAEL M · 2018 to 2022
$1.6M
Identification and functional analysis of novel human-specific small vessel disease proteinsR21NS099783 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, MICHAEL M · 2016 to 2017
$347k
Pathological protein generation in cerebral small vessel diseaseI01BX003824 · VA · VETERANS HEALTH ADMINISTRATION · PI Michael M Wang · 2017 to 2026
–
Transformation of NOTCH3 protein in cerebral small vessel diseaseI01BX003855 · VA · VETERANS HEALTH ADMINISTRATION · PI WANG, MICHAEL M · 2018 to 2021
–
BLRD VA I01 BX003824BLRD VA I01 BX003855NINDS NIH HHS R01 NS099160NINDS NIH HHS R21 NS099783
6 · The paper itself

Abstract

Omeprazole is the most commonly used proton pump inhibitor (PPI), a class of medications whose therapeutic mechanism of action involves formation of a disulfide linkage to cysteine residues in the H+/K+ ATPase pump on gastric secretory cells. Covalent linkage between the sole sulfur group of omeprazole and selected cysteine residues of the pump protein results in inhibition of acid secretion in the stomach, an effect that ameliorates gastroesophageal reflux and peptic ulcer disease. PPIs, though useful for specific conditions when used transiently, are associated with diverse untoward effects when used long term. The mechanisms underlying these potential off-target effects remain unclear. PPIs may, in fact, interact with non-canonical target proteins (non-pump molecules) resulting in unexpected pathophysiological effects, but few studies describe off-target PPI binding. Here, we describe successful cloning of monoclonal antibodies against protein-bound omeprazole. We developed and used monoclonal antibodies to characterize the protein target range of omeprazole, stability of omeprazole-bound proteins, and the involvement of cysteines in binding of omeprazole to targets. We demonstrate that a wide range of diverse proteins are targeted by omeprazole. Protein complexes, detected by Western blotting, are resistant to heat, detergents, and reducing agents. Reaction of omeprazole occurs with cysteine-free proteins, is not fully inhibited by cysteine alkylation, occurs at neutral pH, and induces protein multimerization. At least two other clinically used PPIs, rabeprazole and tenatoprazole, are capable of binding to proteins in a similar fashion. We conclude that omeprazole binds to multiple proteins and is capable of forming highly stable complexes that are not dependent on disulfide linkages between the drug and protein targets. Further studies made possible by these antibodies may shed light on whether PPI-protein complexes underlie off-target untoward effects of chronic PPI use.

Indexed as

AnimalsAntibodies, Monoclonal, Murine-DerivedBinding SitesCysteineHEK293 CellsHumansMiceMice, Inbred BALB CMice, Inbred C57BLMultiprotein ComplexesOmeprazoleProtein BindingProton Pump InhibitorsAntibodies, Monoclonal, Murine-DerivedCysteineMultiprotein ComplexesOmeprazoleProton Pump Inhibitors

Identifiers

PMID32946534
PMCPMC7500594
OpenAlexW3087085928

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.